By Denny Jacob
AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.
The U.K. drugmaker said Monday that Imfinzi was approved by the Food and Drug Administration after AstraZeneca secured priority review for it, and that the approval was based on a Phase 3 trial. Specifically, approval was granted to it in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as a treatment after radical cystectomy, or surgery to remove the bladder.
Imfinzi is also approved in Brazil. Regulatory applications are currently under review in the European Union, Japan and several other countries.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 31, 2025 07:38 ET (11:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.